logo

Seagen Inc (SGEN)



Trade SGEN now with
  Date
  Headline
12/20/2022 6:48:07 AM Astellas : FDA Accepts SBLAs For PADCEV Combination For Treatment Of Metastatic Urothelial Cancer
12/12/2022 10:07:54 AM Seagen Announces Results From Phase 2 Trial Of ADCETRIS With Immunotherapy Combination In Classical Hodgkin Lymphoma
11/10/2022 7:07:26 AM Seagen Appoints Sandra Swain To Board
11/10/2022 7:04:40 AM Seagen Appoints David Epstein As CEO
10/27/2022 4:12:26 PM Seagen Q3 Loss/share $1.03 Vs. Loss $1.61 Year Ago
10/27/2022 4:09:40 PM Seagen Inc (SGEN) Has Raised Its 2022 Revenue Estimate To $1820 - $1865 Mln From $1710 - $1795 Mln
9/26/2022 8:06:42 AM Seagen And LAVA Therapeutics Announce Worldwide License Agreement To Develop And Commercialize LAVA-1223
9/19/2022 8:05:10 AM Seagen : TUKYSA -Trastuzumab Combination Granted Priority Review By FDA For HER2-Positive Metastatic Colorectal Cancer
9/12/2022 9:02:23 AM Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer